Clinical Observation on Mosapride Combined with Flupentixol-melitracen in Treating Irritable Bowel Syndrome with Constipation

Background: Irritable bowel syndrome (IBS) is a commonly seen functional bowel disorder.There are many treatment modalities for IBS,but none of them has a perfect efficacy.Aims: To investigate the efficacy and safety of mosapride combined with flupentixol-melitracen,an antianxiety and antidepressant agent,in treating IBS with constipation (IBS-C).Methods: In a randomized trial,68 cases of IBS-C were divided into control group (n=33) and combination group (n=35),receiving oral mosapride citrate capsule 5 mg tid alone or combined with flupentixol-melitracen tablets, 0.5 mg+10 mg qn,respectively for 4 weeks.Scores of clinical symptoms and three mental scales (HAMA,HAMD and SCL-90) were assessed before and after treatment,the clinical efficacy was estimated by analyzing the changes of total symptoms score.Adverse events during the treatment course were observed.Results: Compared with those before treatment,the scores of abdominal pain/discomfort,stool frequency,stool form and total symptoms,as well as the scores of three mental scales,were significantly decreased after 4-week treatment in both the two groups (P0.05),especially in combination group.The overall efficacy rate of combination group was superior to that of control group (88.6% vs.75.8%, P0.05).No severe adverse events were observed during the treatment course.Conclusions: Mosapride combined with flupentixol-melitracen is effective in relieving the clinical symptoms and improving the mental status of IBS-C patients without obvious side effects,and is worthy to be used widely in clinical practice.